Review Article

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy

Table 1

Studies reporting the changes of fasting glucose, HbA1C, and antidiabetic treatment after DAA treatment.

AuthorCountryPatientsGenotypeTreatmentDecrease of the fasting glucose during or after DAA treatmentDecrease of the HbA1C during or after DAA treatmentProportion of patients with the reduction of antidiabetic treatment

Tran,2017 [54]Multi- ethnicGeneral HCV population, 25.4%
prediabetes 5.9% T2DM
Genotype 1Paritaprevir/ ritonavir + dasabuvir + ombitasvirYes, in all patients, patients with prediabetes and T2DMNANA

Ikeda, 2017 [55]JapanT2DMGenotype 1bSofosbuvir + ledipasvirNAYesNA

Meissner, 2015 [56]USAT2DMGenotype 1Sofosbuvir + ribavirinNAYesNA

Hum [57]USAT2DMMostly genotype 1Sofosbuvir + simeprevir or Sofosbuvir + ledipasvir or Paritaprevit/ritonavir + dasabuvir + ombitasvirNAYes9%

Morales, 2016 [58]USAT2DMMostly genotype 1Only sofosbuvir basedNAYes25%

Ciancio, 2018 [59]ItalyT2DMMostly genotype 1Mostly sofosbuvir basedYesYes21%

Fabrizio, 2017 [60]ItalyT2DMMostly genotype 1Mostly sofosbuvir basedYesNANA

Pavone, 2016 [61]ItalyT2DMMostly genotype 1Mostly sofosbuvir basedYesYes23%

Abdel Alem, 2017 [62]EgyptT2DMMostly genotype 4Only sofosbuvir basedYesYesNA

Dawood, 2017 [63]EgyptT2DMGenotype 4Sofosbuvir + daclatasvirYesYes27%

El Sagher, 2018 [64]EgyptT2DMGenotype 4Sofosbuvir + simeprevirYesNANA

Beig, 2018 [65]New ZealandLTx patients, only patients without antidiabetic treatmentMostly genotype 1Mostly sofosbuvir basedyesYes40%

Chaudhury, 2017 [66]USAGeneral population, 31% HIV positive, 17%T2DMGenotype 1Multiple DAANANo3%

NA: not available; T2DM: type 2 diabetes mellitus.